Target Name: FKBP5
NCBI ID: G2289
Other Name(s): 51 kDa FK506-binding protein 5 | HSP90-binding immunophilin | FKBP5_HUMAN | FKBP-5 | FKBP prolyl isomerase 5, transcript variant 1 | Rotamase | PPIase FKBP5 | Peptidyl-prolyl cis-trans isomerase FKBP5 | Ptg-10 | FKBP54 | rotamase | Androgen-regulated protein 6 | FK506-binding protein 5 | FKBP5 variant 1 | androgen-regulated protein 6 | Peptidylprolyl cis-trans isomerase | p54 | P54 | 51 kDa FKBP | FK506 binding protein 5 | FKBP-51 | FKBP prolyl isomerase 5 | 54 kDa progesterone receptor-associated immunophilin | FK506 binding protein 5, transcript variant 2 | PPIase | peptidylprolyl cis-trans isomerase | FKBP5 variant 2 | AIG6 | T-cell FK506-binding protein | Peptidyl-prolyl cis-trans isomerase FKBP5 (isoform 1) | FF1 antigen | FKBP51 | 51 kDa FK506-binding protein

FKBP5: A Potential Drug Target and Biomarker for Chronic Kidney Disease

Introduction

Chronic kidney disease (CKD) is a leading cause of morbidity and mortality worldwide, with an estimated 10 million people affected worldwide. The decline in kidney function can be attributed to various factors, including aging, diabetes, hypertension, and other chronic conditions. As the number of individuals with CKD increases, there is a growing need for new treatments that can slow the progression of the disease and improve quality of life.

One potential drug target for CKD is FKBP5, a 51 kDa protein that is expressed in various tissues and is known to interact with the immunosuppressive drug FK506. In this article, we will discuss FKBP5 as a potential drug target and biomarker for CKD.

FKBP5: Structure and Function

FKBP5 is a member of the B-cell factor-1 (BCF1) family, which includes several similar proteins that are involved in the regulation of cell growth, differentiation, and survival. The FKBP5 protein has a molecular weight of 51 kDa and consists of 254 amino acid residues.

FKBP5 is highly expressed in various tissues, including muscle, heart, kidney, liver, and stem cells. It is also expressed in the blood and lymph fluid. FKBP5 has been shown to play a role in the regulation of inflammation, immune tolerance, and cellular signaling.

One of the most interesting features of FKBP5 is its ability to interact with FK506, an immunosuppressive drug that is commonly used to prevent rejection of transplanted organs. FKBP5 has been shown to enhance the inhibitory effect of FK506 on T cells, which is associated with the development of rejection of transplanted organs.

In addition to its potential role in immunosuppression, FKBP5 has also been shown to play a role in the regulation of cellular signaling. It has been shown to interact with several signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

FKBP5 as a Drug Target

The ability of FKBP5 to interact with FK506 makes it a potential drug target for CKD. By inhibiting FKBP5, it may be possible to reduce the immunosuppressive effects of FK506 and slow the progression of CKD.

There are several different ways that researchers have identified potential drug targets for FKBP5. One approach is to use small molecules or antibodies to inhibit FKBP5 activity. Researchers have shown that several small molecules, including inhibitors of the FKBP5-PKG complex, can inhibit FKBP5 activity. and reduce the immunosuppressive effects of FK506.

Another approach is to use antibodies to target FKBP5 specifically. Researchers have shown that antibodies specific for FKBP5 can reduce the immunosuppressive effects of FK506 in animal models of CKD.

FKBP5 as a Biomarker

In addition to its potential as a drug target, FKBP5 may also be a useful biomarker for the diagnosis and monitoring of CKD. The decline in kidney function that occurs with CKD can be detected early by changes in the levels of certain proteins in the urine.

Research has shown that the levels of FKBP5 in the urine are significantly increased in individuals with CKD compared to individuals without the disease. This suggests that FKBP5 may be a useful biomarker for the diagnosis and monitoring of CKD.

In addition to its potential as a biomarker, FKBP5 may also be a useful target for researchers studying the mechanisms of CKD. As mentioned earlier, FKBP5 has been shown to play a role in the regulation of cellular signaling, including the TGF-β pathway

Protein Name: FKBP Prolyl Isomerase 5

Functions: Immunophilin protein with PPIase and co-chaperone activities (PubMed:11350175). Component of unligated steroid receptors heterocomplexes through interaction with heat-shock protein 90 (HSP90). Plays a role in the intracellular trafficking of heterooligomeric forms of steroid hormone receptors maintaining the complex into the cytoplasm when unliganded (PubMed:12538866). Acts as a regulator of Akt/AKT1 activity by promoting the interaction between Akt/AKT1 and PHLPP1, thereby enhancing dephosphorylation and subsequent activation of Akt/AKT1 (PubMed:28147277). Interacts with IKBKE and IKBKB which facilitates IKK complex assembly leading to increased IKBKE and IKBKB kinase activity, NF-kappaB activation, and IFN production (PubMed:26101251, PubMed:31434731)

More Common Targets

FKBP6 | FKBP7 | FKBP8 | FKBP9 | FKBP9P1 | FKBPL | FKRP | FKSG29 | FKTN | FLACC1 | FLAD1 | FLCN | FLG | FLG-AS1 | FLG2 | FLI1 | FLII | FLJ12825 | FLJ13224 | FLJ16779 | FLJ20021 | FLJ20712 | FLJ25758 | FLJ30679 | FLJ31945 | FLJ32154 | FLJ32255 | FLJ33534 | FLJ36000 | FLJ37201 | FLJ37786 | FLJ38576 | FLJ39095 | FLJ40194 | FLJ42393 | FLJ42627 | FLJ42969 | FLJ43315 | FLJ44342 | FLJ44635 | FLJ45513 | FLJ46875 | FLNA | FLNB | FLNC | FLOT1 | FLOT2 | FLRT1 | FLRT2 | FLRT3 | FLT1 | FLT3 | FLT3LG | FLT4 | FLVCR1 | FLVCR1-DT | FLVCR2 | FLVCR2-AS1 | FLYWCH1 | FLYWCH2 | FMC1 | FMC1-LUC7L2 | FMN1 | FMN2 | FMNL1 | FMNL2 | FMNL3 | FMO1 | FMO2 | FMO3 | FMO4 | FMO5 | FMO6P | FMO9P | FMOD | FMR1 | FMR1-AS1 | FMR1NB | FN1 | FN3K | FN3KRP | FNBP1 | FNBP1L | FNBP1P1 | FNBP4 | FNDC1 | FNDC10 | FNDC11 | FNDC3A | FNDC3B | FNDC4 | FNDC5 | FNDC7 | FNDC8 | FNDC9 | FNIP1 | FNIP2 | FNTA | FNTB | FOCAD